Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
1255 daily bars · split adjusted
Annual filings (FY) with consensus forward estimates (hatched)
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 47.70 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 52.45 | Oscillator | Neutral |
| Williams %R (14) | -29.13 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.82 (Hist 0.34) | Oscillator | Buy |
| Average Directional Index (14) | 43.03 (+DI 14.7 / -DI 23.8) | Trend | Strong Sell |
| EMA 20 | 66.68 | MA | Buy |
| SMA 20 | 66.14 | MA | Buy |
| EMA 50 | 69.04 | MA | Strong Sell |
| SMA 50 | 69.42 | MA | Strong Sell |
| SMA 200 | 74.63 | MA | Strong Sell |
Current price $66.70
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 23, 26 | Citigroup | maintain | Neutral | Neutral |
| Oct 21, 26 | Baird | maintain | Outperform | Outperform |
| Oct 21, 26 | Stifel | maintain | Buy | Buy |
| Oct 21, 26 | BNP Paribas | maintain | Neutral | Neutral |
| Oct 20, 26 | Barclays | maintain | Equal Weight | Equal Weight |
| Oct 19, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Sep 21, 26 | Evercore ISI Group | maintain | Outperform | Outperform |
| Sep 18, 26 | Stifel | maintain | Buy | Buy |
| Sep 17, 26 | Mizuho | maintain | Neutral | Neutral |
TTM vs. 5-year historical average (annual ratios)
| Metric | ADC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 34.4x | 39.1x · sector 35.5x | In line |
| Forward P/E (FY26E) | 35.2x | EPS est. 1.89 | In line |
| Price / Book | 1.2x | 1.3x | In line |
| Price / Sales | 10.2x | 12.2x | Discount |
| EV / EBITDA | 18.4x | 19.3x | In line |
| Return on equity | 3.7% | — | Weak |
| Gross margin | 70.5% | 87.8% | Below hist. |
| Debt / Equity | 0.54 | 0.50 | Moderate |
| Piotroski / Altman Z | 6/9 | Z 1.34 | Distress |
Discounted cash flow model
Stock news · updated daily
NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced initial encouraging Phase 1 results for ARR-217, (MRG007), a cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC) developed in partnership with Lepu Biopharma Co., Ltd., in patients with gastrointestinal malignancies. The findings were presented as part of an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress 2026.
Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026PR NewswireGUANGZHOU, C
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PR NewswireINDI
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain, on October 23-27, 2026. ArriVent plans to host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data and ARR-217 program. To register for the event, click here.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreem
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 20, 2026 | 0.47 | 1.15 | Beat 143.2% | $213.9M |
| Jul 30, 2026 | 0.48 | 0.44 | Miss -7.6% | $205.1M |
| Apr 21, 2026 | 0.48 | 0.50 | Beat 4.4% | $200.8M |
| Feb 10, 2026 | 0.47 | 0.47 | Miss -0.1% | $190.5M |
| Oct 21, 2025 | 0.45 | 0.45 | Beat 0.1% | $183.2M |
| Jul 31, 2025 | 0.45 | 0.44 | Miss -3.0% | $175.5M |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 21, 26 | Agree Richard | director, officer: EXECUTIVE CHAIRMAN OF BOARD | G-Gift | 4,025 | — |
| Oct 21, 26 | Agree Joey | director, officer: PRESIDENT & CEO | G-Gift | 1,150 | — |
| Oct 21, 26 | Agree Joey | director, officer: PRESIDENT & CEO | G-Gift | 1,150 | — |
| Sep 21, 26 | Erlich Craig | officer: CHIEF GROWTH OFFICER | P-Purchase | 1,000 @ $67.55 | $67.55K |
| Sep 16, 26 | Rakolta John Jr | director | P-Purchase | 20,000 @ $68.78 | $1.38M |
| Sep 16, 26 | Agree Joey | director, officer: PRESIDENT & CEO | P-Purchase | 7,360 @ $68.06 | $500.9K |
| Aug 31, 26 | Rakolta John Jr | director | P-Purchase | 10,000 @ $72.42 | $724.2K |
| Aug 28, 26 | Rakolta John Jr | director | P-Purchase | 136 @ $73.52 | $10.00K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 23, 2026 | 2026-10-23 17:02:54 | View |
| 4 | Oct 23, 2026 | 2026-10-23 17:02:17 | View |
| 10-Q | Oct 20, 2026 | 2026-10-20 16:06:27 | View |
| 8-K | Oct 20, 2026 | 2026-10-20 16:05:27 | View |
| 8-K | Oct 2, 2026 | 2026-10-02 07:00:29 | View |
| 4 | Sep 23, 2026 | 2026-09-23 07:00:20 | View |
| 8-K | Sep 22, 2026 | 2026-09-22 16:05:59 | View |
| 424B5 | Sep 18, 2026 | 2026-09-18 16:07:19 | View |
| FWP | Sep 17, 2026 | 2026-09-17 16:06:41 | View |
| FWP | Sep 17, 2026 | 2026-09-17 16:05:47 | View |
Proxy statement (DEF 14A) disclosures